Borregaard ASA (FRA:BO4) Q3 2024 Earnings Call Highlights: Strong Performance in Biosolutions and Fine Chemicals

Borregaard ASA (FRA:BO4) reports robust growth in EBITDA and operating revenues, driven by increased sales volumes and strategic investments.

Author's Avatar
Oct 31, 2024
Summary
  • EBITDA: NOK524 million, up from NOK482 million in the same quarter last year.
  • EBITDA Margin: 27%, close to last year's all-time-high margin.
  • Earnings Per Share (EPS): NOK2.51, compared to NOK2.38 last year.
  • Operating Revenues: Increased by 14% compared to the third quarter of 2023.
  • Biosolutions Sales Volume: Increased by 7% from the same quarter last year.
  • Biosolutions EBITDA: NOK271 million, an improvement of NOK36 million.
  • Biosolutions EBITDA Margin: Increased by close to 2 percentage points to 26.3%.
  • Biomaterials Sales Volume: Increased from below 35,000 tonnes to about 41,000 tonnes.
  • Biomaterials EBITDA: NOK131 million, compared with NOK161 million last year.
  • Fine Chemicals Operating Revenues: Increased by 24% compared to last year.
  • Fine Chemicals EBITDA: NOK122 million, an all-time-high result for this segment.
  • Fine Chemicals EBITDA Margin: Increased to 50%, about 6 percentage points above last year.
  • Cash Flow from Operating Activities: NOK391 million in the third quarter.
  • Investments: NOK287 million, including NOK150 million in Alginor.
  • Net Interest-Bearing Debt: Reduced by NOK97 million in the quarter.
  • Equity Ratio: 56% at the end of the third quarter.
  • Leverage Ratio: 1.15 (net interest-bearing debt over EBITDA).
Article's Main Image

Release Date: October 30, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Borregaard ASA (FRA:BO4, Financial) reported an increase in EBITDA to NOK524 million, up from NOK482 million in the same quarter last year, driven by increased sales volume in biosolutions.
  • The fine chemicals segment delivered a strong performance with significantly higher deliveries in bioethanol and a favorable product mix for pharmaceutical intermediates.
  • The company announced a capacity increase at the biorefinery in Sarpsborg, with an investment of NOK490 million, expected to deliver a 5% to 10% capacity increase by 2027.
  • Operating revenues in biosolutions increased by 8% compared to the third quarter last year, mainly due to higher sales volume in agriculture.
  • Borregaard ASA (FRA:BO4) maintained a strong financial position with an equity ratio of 56% and a leverage ratio of 1.15.

Negative Points

  • Increased wood costs and general cost inflation offset the higher sales volume, impacting the overall financial performance.
  • Biomaterials segment experienced a lower result despite higher deliveries and price increases, due to increased wood costs and operating expenses.
  • The biovanillin market remains challenged by a high supply of synthetic vanillin products, affecting sales.
  • The company anticipates seasonal increases in energy consumption and energy-related raw material prices as winter approaches.
  • Net currency effects were slightly positive but largely offset by increased hedging losses, impacting the financial results.

Q & A Highlights

Q: What is the total CapEx for debottlenecking for both steps?
A: We have presented a number for the first step today. We are not far enough in the process of the second step to give a number for the whole project. However, it will be a lower number for the second step, but still substantial. - Per Lyngstad, Chief Financial Officer

Q: Why are you guiding lower volumes in lignin? What has disappointed?
A: The markets are still soft in some areas, particularly construction-related markets. We assess whether to move products into different areas or inventory with higher values. This balancing effect is what you see now. The agricultural and battery segments have been strong, but construction remains soft. - Per Sorlie, President, Chief Executive Officer

Q: What assumptions for wood cost development going forward would be fair to assume when negotiating prices for 2025?
A: Several factors drive wood prices, including geopolitical events and EU regulations on sustainable forest management. We expect wood to become more scarce, leading to higher costs. Negotiations for the first half of 2025 will occur towards the end of the year. - Per Sorlie, President, Chief Executive Officer

Q: Which families of products in your agriculture portfolio are doing well, and what are the selling points valued by clients?
A: We have a diverse portfolio with close to 100 products in agriculture. There is no particular pattern; we sell across the spectrum from granulation to biostimulants. Our offerings are well-timed with market recovery, which clients appreciate. - Per Sorlie, President, Chief Executive Officer

Q: Can you comment on the main drivers for the uptick in deliveries for fine chemicals and the visibility going forward?
A: Fine chemical intermediates and bioethanol have variable delivery patterns. The strong deliveries this quarter are not indicative of a permanent increase. The fine chemical intermediates market is stable, while bioethanol is driven by EU biofuel demand. Long-term, we aim to position bioethanol in pharmaceuticals. - Per Sorlie, President, Chief Executive Officer

For the complete transcript of the earnings call, please refer to the full earnings call transcript.